Solstice Oncology secures $225M Series A to advance CTLA-4 antibody porustobart in colon cancer
Solstice Oncology, a biotech startup focused on immunotherapy, announced it has raised $225 million in a Series A financing round.
The funding will support development of its lead candidate, a CTLA-4 targeting antibody named porustobart, which the company plans to test in colon cancer patients before they receive other therapies.
Porustobart was licensed from Chinese developer Harbour Biomed in February, with an upfront payment of $105 million and a potential total deal value of $1.2 billion.
Investors in the round include venture firms such as RA Capital Management, Canaan Partners and Forbion, underscoring confidence in the company's approach to a challenging immunotherapy target.
This writeup was produced by pharmadog from original reporting by BioPharma Dive.
Original headline: “A new immuno-oncology play raises $225M for a next-generation drug”
read at BioPharma Dive ↗
comments(0)
5-min edit window · permanent after that